PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 26, 2026BMC Pediatrics0 citationsOpen Access

Distinguishing acute lymphoblastic leukemia from juvenile idiopathic arthritis in children with musculoskeletal complaints: a retrospective cross-sectional study

MTMahdieh Mousavi TorshiziRBRazieh BordbarESElham Shahgholi

Key Points

  • The central aim was to identify clinical and laboratory features that can differentiate acute lymphoblastic leukemia from juvenile idiopathic arthritis in children with musculoskeletal complaints.
  • Conducted a retrospective cross-sectional study in hospitalized children under 16 at Bahrami Children’s Hospital
  • Extracted data on demographics, symptoms, and lab results from first hospital presentation
  • Used multivariable logistic regression analysis to identify predictors for both conditions
  • Symptom duration was significantly shorter in acute lymphoblastic leukemia compared to juvenile idiopathic arthritis (median, 3 vs. 90 days)
  • Systemic features like fever (83% vs. 27%), weakness (45% vs. 5%), and weight loss (35% vs. 5%) were more common in acute lymphoblastic leukemia
  • Bone pain was prevalent in acute lymphoblastic leukemia (93% vs. 35%), while objective arthritis was rare
  • Lower hemoglobin and platelet counts were observed in acute lymphoblastic leukemia compared to juvenile idiopathic arthritis
  • Discrimination for acute lymphoblastic leukemia was very high (0.994) as per area under the receiver operating characteristic curve

Abstract

To identify routinely available clinical and laboratory features that differentiate acute lymphoblastic leukemia (ALL) from juvenile idiopathic arthritis (JIA) among children presenting with musculoskeletal complaints and no peripheral blood blasts at initial evaluation. A retrospective cross-sectional study was conducted among hospitalized children younger than 16 years at Bahrami Children’s Hospital (Tehran, Iran) between 2013 and 2023. Eligible children presented with musculoskeletal symptoms and were subsequently diagnosed with ALL based on bone marrow examination with immunophenotyping or with JIA by a pediatric rheumatologist according to International League of Associations for Rheumatology criteria. Children who received systemic corticosteroids before a definitive diagnosis, had blasts on the peripheral blood smear, or had > 30% missing data were excluded. Demographic characteristics, symptoms, physical examination findings, and initial laboratory results were extracted from the first hospital presentation. Multivariable logistic regression was used to identify independent predictors, with bootstrap internal validation. Sixty-six children met the inclusion criteria (29 ALL; 37 JIA). Symptom duration before diagnosis was markedly shorter in ALL than in JIA (median, 3 vs. 90 days). Systemic features were more frequent in ALL, including fever (83% vs. 27%), weakness (45% vs. 5%), and weight loss (35% vs. 5%). Bone pain was more common in ALL (93% vs. 35%), whereas objective arthritis—particularly knee involvement—was uncommon (14% vs. 87%); absence of clinical arthritis was frequent (62% vs. 3%). Splenomegaly (41% vs. 3%) and hepatomegaly (38% vs. 0%) occurred more often in ALL. Laboratory testing showed lower hemoglobin and platelet counts in ALL (median hemoglobin 7.5 vs. 11.7 g/dL; platelets 75 × 10³ vs. 317 × 10³/µL), with lower neutrophil counts and higher inflammatory markers (ESR and CRP) and LDH levels. In multivariable analysis, lower hemoglobin concentration and shorter symptom duration were independently associated with ALL; discrimination was 0.994 (bootstrap-corrected 0.990), as assessed by the area under the receiver operating characteristic curve. In children with musculoskeletal complaints and no peripheral blood blasts, rapid symptom onset accompanied by systemic features, predominant bone pain, organomegaly, cytopenias, and elevated LDH strongly suggests ALL rather than JIA. Because inflammatory markers may also be elevated in ALL, these features should prompt early evaluation to exclude leukemia before initiating corticosteroids or other immunosuppressive therapy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Torshizi et al. (2026) studied this question.

synapsesocial.com/papers/69c4cda5fdc3bde44891a468https://doi.org/10.1186/s12887-026-06701-0
Ask AI
Helpful
Bookmark
Share
View Full Paper